Home » Stocks » CTIC

CTI BioPharma Corp. (CTIC)

Stock Price: $2.20 USD -0.02 (-0.68%)
Updated May 13, 2021 3:28 PM EDT - Market open
Market Cap 208.95M
Revenue (ttm) n/a
Net Income (ttm) -57.53M
Shares Out 76.37M
EPS (ttm) -0.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $2.20
Previous Close $2.21
Change ($) -0.02
Change (%) -0.68%
Day's Open 2.22
Day's Range 2.18 - 2.25
Day's Volume 412,374
52-Week Range 0.96 - 4.13

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SEATTLE, May 12, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity in...

19 hours ago - PRNewsWire

SEATTLE, May 5, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its first quarter 2021 financial results on Tuesday, June 1, 2021,...

1 week ago - PRNewsWire

SEATTLE, April 21, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity ...

3 weeks ago - PRNewsWire

Many penny stocks are destined for bankruptcy, but there are some that will survive. Wall Street thinks these companies are undervalued.

Other stocks mentioned: ABEO, EFOI, FBIO, IO, PXLW, SYBX
3 weeks ago - InvestorPlace

SEATTLE, April 7, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 20th Annual Needham Virtual Healthcare Conference at 3:...

1 month ago - PRNewsWire

CTI BioPharma's (NASDAQ:CTIC) stock has been falling Thursday, down 13.06% to a price of $2.55. Thursday the stock has been traded at a volume of 2.13 million, about 326.0% of its recent 30-day volume a...

1 month ago - Benzinga

SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies ...

1 month ago - PRNewsWire

SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies ...

1 month ago - PRNewsWire

CTI BioPharma Corp (NASDAQ: CTIC) has completed a rolling marketing application submission to the FDA seeking approval of pacritinib for myelofibrosis patients with severe thrombocytopenia (platelet cou...

1 month ago - Benzinga

SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has completed a rolling New Drug Application ("NDA") submission to the U.S. Food and Drug Administratio...

1 month ago - PRNewsWire

CTI BioPharma Corp (NASDAQ: CTIC) has announced that Clinical Cancer Research, a journal of the American Association for Cancer Research, has published results from a Phase 1 study evaluating pacritinib...

1 month ago - Benzinga

SEATTLE, March 22, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), today announced that Clinical Cancer Research, a journal of the American Association for Cancer Research, has published result...

1 month ago - PRNewsWire

SEATTLE, March 17, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2020. "This past quarter, CTI has ...

1 month ago - PRNewsWire

SEATTLE, March 12, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its fourth quarter and full year 2020 financial results on Wedn...

2 months ago - PRNewsWire

SEATTLE, Jan. 28, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees with a gran...

3 months ago - PRNewsWire

Innovation paid off big for investors.

Other stocks mentioned: AQB, IBIO, ALPN
4 months ago - The Motley Fool

SEATTLE, Dec. 8, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at The JMP Securities Hematology Summit at 3:00 p.m. EST. The c...

5 months ago - PRNewsWire

CTIC recently received FDA's accelerated approval go-ahead for pacritinib in MF patients with severe thrombocytopenia. This considerably reduces the risks associated with the company.

5 months ago - Seeking Alpha

SEATTLE, Dec. 6, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation supporting the Company's pacritinib development program in the prevention of acute graft ver...

5 months ago - PRNewsWire

SEATTLE, Nov. 30, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that an article highlighting pacritinib data was published in Blood Advances. The article, titled "Determining t...

5 months ago - PRNewsWire

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

SEATTLE, Nov. 4, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation supporting the Company's pacritinib development program in graft versus host disease (GVHD) ...

6 months ago - PRNewsWire

SEATTLE, Nov. 2, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2020 financial results on Tuesday, November 10,...

6 months ago - PRNewsWire

CTI BioPharma (CTIC) news for Wednesday includes plans to submit a new drug application (NDA) sending CTIC stock soaring higher. The post CTI BioPharma News: Why CTIC Stock Is Skyrocketing 104% Today ap...

7 months ago - InvestorPlace

CTI BioPharma: A Nano Cap With Interesting Prospects

8 months ago - Seeking Alpha

SEATTLE, June 1, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of pacritinib in hospitalized ...

11 months ago - PRNewsWire

SEATTLE, May 28, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies 2020 Healthcare Conference at ...

11 months ago - PRNewsWire

CTI Biopharma Accelerated Review, And Other News: The Good, Bad, And Ugly Of Biopharma

1 year ago - Seeking Alpha

About CTIC

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was former... [Read more...]

Industry
Biotechnology
IPO Date
Mar 21, 1997
CEO
Adam Craig
Employees
22
Stock Exchange
NASDAQ
Ticker Symbol
CTIC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for CTI BioPharma stock is "Buy." The 12-month stock price forecast is 6.70, which is an increase of 205.24% from the latest price.

Price Target
$6.70
(205.24% upside)
Analyst Consensus: Buy